A Brazilian man known online as the “Living Nostradamus” has issued a new warning—this time about the rapid rise in weight-loss medications such as Ozempic, Wegovy, and Mounjaro. These GLP-1 drugs were originally designed to help people with diabetes manage blood sugar, but their strong appetite-reducing effects have made them enormously popular for weight loss in recent years.
Although millions have embraced the medications, questions remain about their long-term safety. Athos Salomé, the 38-year-old seer who claims to have predicted global events such as the Covid-19 pandemic and Queen Elizabeth II’s death, believes 2026 may bring new concerns.
Speaking to Tyla, Salomé said he foresees a rise in cases of subclinical pancreatitis—a hard-to-detect inflammation of the pancreas—as more people rely on GLP-1 drugs. He also predicts “medication fatigue,” meaning patients may stop responding to the drugs after two or more years of continuous use.
He believes governments will increasingly depend on these medications to help reduce healthcare costs and hospital strain, creating a new kind of pharmaceutical dependence. With nearly 12% of Americans already using GLP-1 drugs for weight loss—especially women ages 50 to 64—his concerns are gaining attention.
Doctors already warn that these medications can cause side effects including nausea, vomiting, diarrhea, and in some cases, dramatic facial thinning known as “Ozempic face.” Pancreatitis is also a known risk.
Salomé adds that global competition is shifting, with new companies entering the market and governments reassessing their reliance on major drug makers. He predicts weight-loss medications may even become tools in international politics as countries look for cost-effective ways to manage public health.
